Compare MBBC & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | HOWL |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 29.7M |
| IPO Year | N/A | 2021 |
| Metric | MBBC | HOWL |
|---|---|---|
| Price | $13.25 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 3.1K | ★ 423.0K |
| Earning Date | 02-11-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $7,936,063.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.79 | ★ N/A |
| Revenue Growth | ★ 21.07 | N/A |
| 52 Week Low | $9.34 | $0.53 |
| 52 Week High | $13.75 | $2.38 |
| Indicator | MBBC | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 47.92 |
| Support Level | $12.75 | $0.59 |
| Resistance Level | $13.75 | $0.74 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 65.99 | 31.78 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.